BEAM
BEAM
NASDAQ · Biotechnology

Beam Therapeutics Inc

$24.63
-0.54 (-2.15%)
As of Mar 22, 10:00 PM ET ·
Financial Highlights (FY 2026)
Revenue
80.30M
Net Income
-476,226,747
Gross Margin
Profit Margin
-593.1%
Rev Growth
+7.0%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 48.9% 48.9%
Operating Margin -654.2% -588.8% -6.1% -6.1%
Profit Margin -593.1% -563.5% -9.9% -9.6%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 80.30M 75.04M 476.44M 432.89M
Gross Profit 233.13M 211.83M
Operating Income -525,332,890 -441,827,493 -29,234,950 -26,348,592
Net Income -476,226,747 -400,527,121 -46,993,180 -41,441,136
Gross Margin 48.9% 48.9%
Operating Margin -654.2% -588.8% -6.1% -6.1%
Profit Margin -593.1% -563.5% -9.9% -9.6%
Rev Growth +7.0% +7.0% -6.6% +15.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 420.07M 396.17M
Total Equity 1.92B 2.06B
D/E Ratio 0.22 0.19
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -495,580,060 -439,959,870 -41,088,618 -32,500,848
Free Cash Flow -33,034,013 -43,893,077